Patient-reported QOL and symptom outcomes were similar between belzutifan plus lenvatinib and cabozantinib in previously treated RCC.
Commentary|Videos|September 15, 2024
Dr Choueiri on Lessons Learned from the TiNivo-2 Study in Metastatic RCC
Author(s)Toni Choueiri, MD
Fact checked by: Ashling Wahner , Kristi Rosa
Toni Choueiri, MD, discusses findings with tivozanib plus nivolumab in metastatic RCC after progression on an immune checkpoint inhibitor.
Advertisement
Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, co-leader, kidney cancer program, Dana-Farber Cancer Institute; Jerome and Nancy Kohlberg Chair, professor, medicine, Harvard Medical School, discusses findings from the phase 3 TiNivo-2 trial (NCT04987203) investigating tivozanib (Fotivda) plus nivolumab (Opdivo) vs tivozanib monotherapy in patients with metastatic renal cell carcinoma (RCC) who had previously progressed on or after an immune checkpoint inhibitor (ICI).
Advertisement
Related to this article
Adanma Ayanambakkam, MD, MS, discusses findings from the FIT-001 trial of darlifarnib plus cabozantinib in RCC.
The top 5 OncLive TV videos of the week cover pancreatic cancer, gastric cancer, GIST, renal cell carcinoma, and chronic lymphocytic leukemia.
The FDA approved daraxonrasib for pancreatic cancer, cleared zanidatamab-based regimens for HER2-positive gastric cancer, and more.
ASCO issued an alert regarding dwindling supplies of ifosfamide, which is used across testicular cancer and sarcoma regimens.
Subcutaneous amivantamab produced a 42% objective response rate and a 15% complete response rate in patients with recurrent/metastatic HNSCC.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer
2
Brachytherapy and Minimally Invasive Surgical Techniques Signal the Future of Brain Cancer Management
3
Datopotamab Druxtecan and ADC Toxicity Management in EGFR-Mutant NSCLC
4
Selecting Frontline Therapy for High-Risk EGFR-Mutated NSCLC
5